This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Nov 16;142(20):1673-1674.

doi: 10.1182/blood.2023022244.

Gemtuzumab ozogamicin in AML: the next chapter

Christoph Röllig¹

Affiliations

PMID: 37971761
DOI: 10.1182/blood.2023022244

Free article

Editorial

Gemtuzumab ozogamicin in AML: the next chapter

Christoph Röllig. Blood. 2023.

Free article

. 2023 Nov 16;142(20):1673-1674.

doi: 10.1182/blood.2023022244.

Author

Christoph Röllig¹

Affiliation

¹ Universitätsklinikum TU Dresden.

PMID: 37971761
DOI: 10.1182/blood.2023022244

No abstract available

PubMed Disclaimer

Comment on

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Freeman SD, Thomas A, Thomas I, Hills RK, Vyas P, Gilkes A, Metzner M, Jakobsen NA, Kennedy A, Moore R, Almuina NM, Burns S, King S, Andrew G, Gallagher KME, Sellar RS, Cahalin P, Weber D, Dennis M, Mehta P, Knapper S, Russell NH. Freeman SD, et al. Blood. 2023 Nov 16;142(20):1697-1707. doi: 10.1182/blood.2023020630. Blood. 2023. PMID: 37595359 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information